Department of Leukemia, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China,
Molecular Biology Laboratory, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Acta Haematol. 2022;145(5):560-565. doi: 10.1159/000524275. Epub 2022 Mar 25.
Through an RNA-seq analysis of an adult patient with unclassifiable myelodysplastic/myeloproliferative neoplasms (MDS/MPN-U), we identified a rare PDGFRB fusion partner gene, PCM1. Conventional chromosome karyotype analysis showed abnormal clones of t(5;8)(q32;p22), and fluorescence in situ hybridization (FISH) confirmed rearrangement of the PDGFRB gene. Reverse transcription PCR (RT-PCR) and Sanger sequencing further confirmed that exon 30 of the PCM1 gene was fused with exon 11 of PDGFRB in frame, and the fusion event was accompanied by a 14 bp deletion of exon 11 of PDGFRB. After low-dose imatinib treatment, the patient achieved complete molecular remission. This study not only broadens the understanding of myeloid/lymphoid neoplasms with PDGFRB rearrangement but also reflects the vital role of RNA-seq in identifying PDGFRB rearrangements.
通过对一例无法分类的骨髓增生异常/骨髓增殖性肿瘤(MDS/MPN-U)成年患者进行 RNA-seq 分析,我们鉴定出一种罕见的 PDGFRB 融合伙伴基因 PCM1。常规染色体核型分析显示 t(5;8)(q32;p22) 的异常克隆,荧光原位杂交(FISH)证实 PDGFRB 基因重排。逆转录 PCR(RT-PCR)和 Sanger 测序进一步证实 PCM1 基因的外显子 30 与 PDGFRB 的外显子 11 框内融合,融合事件伴有 PDGFRB 外显子 11 的 14 个碱基缺失。在低剂量伊马替尼治疗后,患者达到完全分子缓解。本研究不仅拓宽了对具有 PDGFRB 重排的髓系/淋系肿瘤的认识,也反映了 RNA-seq 在鉴定 PDGFRB 重排方面的重要作用。